Opexa Therapeutics (NASDAQ: ACER) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Opexa Therapeutics to similar businesses based on the strength of its earnings, analyst recommendations, risk, dividends, valuation, institutional ownership and profitability.

Risk and Volatility

Opexa Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. Comparatively, Opexa Therapeutics’ competitors have a beta of 5.91, meaning that their average share price is 491% more volatile than the S&P 500.

Profitability

This table compares Opexa Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opexa Therapeutics N/A -108.02% -88.85%
Opexa Therapeutics Competitors -5,311.45% -218.34% -39.53%

Institutional and Insider Ownership

0.3% of Opexa Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 6.9% of Opexa Therapeutics shares are owned by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Opexa Therapeutics and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Opexa Therapeutics $2.90 million -$7.97 million -2.53
Opexa Therapeutics Competitors $284.28 million $34.29 million 81.86

Opexa Therapeutics’ competitors have higher revenue and earnings than Opexa Therapeutics. Opexa Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Opexa Therapeutics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opexa Therapeutics 0 0 0 0 N/A
Opexa Therapeutics Competitors 857 3201 11603 231 2.71

As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.19%. Given Opexa Therapeutics’ competitors higher possible upside, analysts clearly believe Opexa Therapeutics has less favorable growth aspects than its competitors.

Summary

Opexa Therapeutics competitors beat Opexa Therapeutics on 7 of the 9 factors compared.

Opexa Therapeutics Company Profile

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

Receive News & Ratings for Opexa Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.